Close

FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'

Go back to FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'

Seres Therapeutics (MCRB) Misses Q2 EPS by 24c

August 11, 2016 7:02 AM EDT

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

... More

Trading Radar for 8/11: NVIDIA (NVDA), Macy's (M), Himax (HIMX), Nordstrom (JWN), voxeljet (VJET) Report

August 10, 2016 3:09 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Initial Claims - Street sees 266kContinuing Claims - no Street consensusExport Prices ex. ag - no Street consensusImport Prices ex. oil - no Street consensus

Earnings:

AIXTRON SE (Nasdaq: AIXG) - consensus loss $0.11
Akers Biosciences (Nasdaq: AKER) - no Street consensus
Alibaba (Nasdaq: BABA) - consensus EPS $0.63
American DG Energy (Nasdaq:... More